MELBOURNE, Australia, December 5, 2025 (EZ Newswire) -- iNGENū CRO, a global contract research organization, has set out the main operational factors it says enable sponsors to run clinical trials at lower cost while meeting international regulatory standards.

The company said the approach combines the use of cost-efficient global trial locations, access to government R&D incentive programs and the adoption of modern trial technologies intended to streamline monitoring and data collection.

Global Trial Locations

iNGENū CRO conducts trials in jurisdictions that adhere to ICH-GCP requirements, with data accepted by major regulators including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

These markets offer established ethics review processes, experienced investigators and lower overhead than traditional U.S. and European trial centres, the company said.

Government Incentives

Several of the regions in which the company operates provide R&D tax incentives or grant schemes that can offset clinical development costs. These programs reduce net expenditure for sponsors without adding regulatory complexity, by virtue of a Government bursary.